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Abstract
Background: Mast cells play a key role in asthma and recent evidence indicates that their ongoing
activation in this disease is mediated, in part, via IgE in the absence of antigen. In this study we have
examined whether IgE alone enhances human lung mast cell (HLMC) survival.
Methods: Purified HLMC were cultured for 4 weeks and survival assays then performed over 10
days following cytokine withdrawal in the presence or absence of human myeloma IgE. Quantitative
real time RT-PCR was carried out to examine IL-6 mRNA expression and IL-6 protein was
measured in HLMC supernatants by ELISA.
Results: IgE alone promoted the survival of HLMC in a dose-dependent manner following cytokine
withdrawal. IgE-induced survival was eliminated with the addition of neutralising anti-IL-6 antibody
but not by the addition of neutralising anti-stem cell factor. IgE sensitisation initiated profound
upregulation of IL-6 mRNA in HLMC, and IL-6 concentrations were also raised in the culture
supernatants of IgE-exposed cells.
Conclusion: These data taken together suggest that IgE in the absence of antigen promotes HLMC
survival through the autocrine production of IL-6. This provides a further mechanism through
which IL-6 and IgE contribute to the pathogenesis of asthma, and through which anti-IgE therapy
might achieve its therapeutic effect.
Background
Mast cells play a key role in many physiological and
pathophysiological processes. They contribute to the
maintenance of tissue homeostasis, wound repair [1,2]
and revascularisation [3], as well as exerting protective
roles in both acquired and innate immune responses to
bacterial infection [4]. However, mast cells are synony-
mous with allergy due to the destructive effects of their
mediators when released in excess through IgE-dependent
mechanisms. In asthma, mast cells infiltrate the airway
smooth muscle (ASM) bundles, airway epithelium and
submucosal glands, placing them in direct contact with
these dysfunctional airway elements [5].
Mast cells can be activated by many diverse stimuli lead-
ing to mediator release but allergen-dependent activation
occurs predominantly through the high affinity IgE recep-
tor complex (FcεRI) following aggregation of allergen-spe-
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cific IgE bound to FcεRI (Reviewed in [6,7]). IgE binding
to FcεRI in the absence of antigen has long been consid-
ered to represent a passive sensitisation of mast cells.
However, this view has been challenged due to increasing
evidence that monomeric IgE binding to FcεRI initiates
intracellular signalling events leading to distinct cellular
responses [8-19]. IgE alone directly activates human lung
mast cells (HLMC) leading to Ca2+ influx and the release
of histamine, leukotriene C4 (LTC4) and CXCL8 [8]. Thus
increased IgE production in atopic asthma could directly
contribute to the mast cell hypersecretion and prolonged
activation evident within asthmatic bronchi [5].
Understanding the mechanisms of mast cell hyperplasia
in diseased tissue structures is of interest because inhibit-
ing this might offer new approaches to treatment.
Increased mast cell recruitment by the asthmatic ASM for
example appears to be one factor [20]. However enhanced
mast cell survival might be a further factor. In rodents, IgE
not only activates mast cells leading to mediator release,
but also prolongs their survival through the autocrine pro-
duction of survival-enhancing cytokines, particularly IL-3
[21]. IgE-dependent mast cell survival may therefore also
be a factor contributing to the increased numbers of mast
cells evident in key airway structures of the asthmatic air-
way.
In this study, we have tested the hypothesis that IgE alone
enhances HLMC survival through the production of the
survival enhancing cytokines IL-6 and stem cell factor. We
demonstrate for the first time that monomeric IgE in the
absence of antigen enhances HLMC survival, and that this
effect is mediated, at least in part, through the autocrine
production of IL-6.
Results
IgE alone promotes HLMC survival following cytokine 
withdrawal
Human lung mast cells undergo apoptosis with SCF and
IL-6 withdrawal [22]. We therefore tested the effects of IgE
alone on mast cell survival following SCF, IL-6 and IL-10
withdrawal. Following cytokine withdrawal, there was
evidence of a decrease in cell viability in the control cells,
which contained no IgE, even as early as 24 hours which
was significant by day 3 (Figure 1A) (p = 0.020, n = 6).
There was a significant dose-dependent increase in HLMC
viability with the addition of IgE by day 7 when compared
to the sodium azide control (Figure 1A). Thus at day 7,
HLMC % viability was 11.0 ± 6.0% in the control com-
pared to 13.3 ± 7.5% with 0.00015% sodium azide (p =
0.3419, n = 6). With the addition of 0.1, 0.3, 1 and 3 μg/
ml IgE, HLMC % viability was 21.3 ± 8.8, 25.4 ± 8.2, 26.9
± 7.6 and 30.5 ± 7.0% respectively (Figure 1A) (p =
0.0397, p = 0.0056, p = 0.0214 and p = 0.0014 respec-
tively, n = 6). Interestingly, we found there to be no signif-
icant difference between the sodium azide control and the
cells alone at either days 1, 3, 7 or 10 (p = 0.3781, p =
0.9595, p = 0.3419 and p = 0.7462 respectively, n = 6).
In order to determine the mechanism of the enhancement
of mast cell survival with IgE we next investigated the
autocrine production of the pro-survival cytokines SCF
and IL-6. There was absolutely no effect on survival with
the addition of neutralising anti-SCF (1 μg/ml) or isotype
control antibodies (Figure 1B). However, with the addi-
tion of neutralising anti-IL-6 (1 μg/ml) there was a
marked decrease in the number of viable cells compared
to the isotype control (Figure 1B). Thus in the isotype con-
trol, there were 2467 ± 309 viable cells at day 7 compared
to 517 ± 204 viable cells with the addition of anti-IL-6
(Figure 1B) (p = 0.041, n = 3). As an additional control,
we also investigated the effects of IgG on HLMC survival.
Thus with the addition of 3 μg/ml IgE, there were 2008 ±
143 viable cells at day 7 compared to 712 ± 189 viable
cells with the addition of 3 μg/ml IgG (Figure 1C) (p =
0.005, n = 4). Therefore, the addition of IgG did not affect
HLMC survival when compared to the sodium azide con-
trol (712 ± 189 viable cells with 3 μg/ml IgG, compared to
906 ± 208 viable cells in the sodium azide control, Figure
1C, p = 0.515, n = 4).
Quantitative real time RT-PCR
In order to confirm that IL-6 expression in HLMC was
upregulated with the addition of IgE alone, comparative
quantitative real time RT-PCR was carried out and the rel-
ative expression of IL-6 mRNA in IgE (3 μg/ml)-stimu-
lated cells compared to unstimulated cells. The relative
expression of IL-6 mRNA in the IgE-stimulated cells was
increased 46997 ± 41171 fold compared to control (Fig-
ure 2) (p = 0.043, n = 14) when calculated with the
Mx3000P's built in algorithm with an adaptive baseline.
The degree of upregulation was highly variable, but was
consistently greater than the control which in 2 donors
did not achieve Ct even after 50 cycles (Figure 3). The 2
donors where the control reaction did not reach Ct had a
relative expression of 577000 and 80591, which accounts
for the huge relative expression and variability when the
mean is plotted. We therefore analysed the data using the
median and range. The median (range) relative expression
of IL-6 mRNA was 3.79 (1.01–577000) when compared
to control.
Due to this inherent variability, and since the determina-
tion of relative expression can vary greatly depending on
the algorithm used, we next confirmed the gene upregula-
tion using the 2-ΔΔCt method which has been validated as
a good measure of relative gene expression [23]. The mean
Ct Target – Ct Calibrator for IL-6 in the control was 17.93. With
the addition of 3 μg/ml IgE, the mean Ct Target – Ct Calibrator
was 13.62 (p = 0.018, n = 14). Thus using the 2-ΔΔCt calcu-BMC Immunology 2008, 9:2 http://www.biomedcentral.com/1471-2172/9/2
Page 3 of 9
(page number not for citation purposes)
lation, the relative expression of IL-6 following IgE stimu-
lation was upregulated by 29445 ± 21013 (Figure 2),
which is comparable to the data from the Mx3000P algo-
rithm. The median (range) relative expression of IL-6
mRNA was 3.38 (1.0–267652) when compared to control
using the 2-ΔΔCt algorithm. For statistical analysis, Ct data
was imported into the Relative Expression Software Tool
(REST 2005, version 1.9.12, Corbett Life Science) which
uses a different algorithm. The relative expression using
the REST algorithm was almost identical to the 2-ΔΔCt algo-
rithm with an upregulation of 29445 ± 21013 (Figure 2),
which after bootstrapping with 50 000 iterations was sig-
nificant (p = 0.043, n = 14).
A dissociation curve was performed on all experiments
and a distinct peak was observed consistently around
79.5°C for IL-6 and around 85.8°C for β-actin (Figure 4).
QRT-PCR products were run on a 1.5% agarose gel to
determine the product size and the IL-6 product was
indeed 250 bp and β-actin was 310 bp (Figure 5). Bands
were gel excised, purified and sequenced which confirmed
specificity.
Measurement of IL-6 release using ELISA
To confirm that the upregulation of IL-6 transcription
with the addition of IgE was associated with an increased
release of IL-6, we next measured the IL-6 released into the
IgE promotes the survival of cultured human lung mast cells through IL-6 Figure 1
IgE promotes the survival of cultured human lung mast cells through IL-6. A) Survival assay time course following 
cytokine withdrawal. Human lung mast cells (HLMC) die rapidly following cytokine withdrawal and this cell death is attenuated 
with the addition of IgE. B) IgE-induced HLMC survival is eliminated with the addition of an anti-IL-6 antibody and unaffected 
with the addition of an anti-SCF antibody following 7 days of culture. C) IgG does not promote HLMC survival when com-
pared to the sodium azide control. Data is presented as the mean ± SEM from 6 different donors performed in triplicate. 
Blocking experiments are the mean ± SEM from 3 donors. Data for the IgG control experiments are the mean ± SEM from 4 
donors. Donors in C are different to those in A and B.BMC Immunology 2008, 9:2 http://www.biomedcentral.com/1471-2172/9/2
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supernatants after 7 days of cytokine withdrawal. This
revealed a dose-dependent increase in IL-6 release with
the addition IgE. Thus with the addition of 3 μg/ml IgE,
net IL-6 release was 71.3 ± 25.8 pg/ml (Figure 6) (p =
0.034, n = 6). Total IL-6 concentration with 3 μg/ml IgE
was 426 ± 62 pg/ml of culture medium.
Discussion
This study makes the novel observation that IgE in the
absence of antigen promotes the survival of HLMC fol-
lowing cytokine withdrawal. This survival advantage is
associated with increases in HLMC IL-6 mRNA expression
and protein release, and is abrogated by neutralising anti-
Monomeric IgE induces the upregulation of IL-6 mRNA transcription in freshly isolated human lung mast cells Figure 2
Monomeric IgE induces the upregulation of IL-6 mRNA transcription in freshly isolated human lung mast cells. 
Human lung mast cell IL-6 mRNA expression was determined using comparative quantitative real time RT-PCR and upregula-
tion of expression was confirmed using three different algorithms for calculation of results.
Amplification plots for quantitative real time RT-PCR demonstrating the heterogeneity of IL-6 mRNA expression Figure 3
Amplification plots for quantitative real time RT-PCR demonstrating the heterogeneity of IL-6 mRNA expres-
sion. A) Amplification plot of a donor with low expression of IL-6 mRNA even after IgE stimulation and no Ct in the control 
cells. B) Amplification plot of a donor with higher expression of IL-6 mRNA including constitutive expression in the unstimu-
lated cells. All donors exhibited upregulation of mRNA expression with the addition of IgE.BMC Immunology 2008, 9:2 http://www.biomedcentral.com/1471-2172/9/2
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body to IL-6 but not SCF. This suggests that IgE-dependent
HLMC survival is mediated, in part, through the autocrine
production of IL-6.
We have found that in the presence of clinically relevant
concentrations of IgE (1 μg/ml = ~400 kU/L), HLMC sur-
vival is enhanced following growth factor withdrawal.
Although SCF is the major growth and survival factor for
HLMC, and is released by them in an autocrine manner
[24], IgE-dependent survival was not accounted for via an
SCF-dependent mechanism because neutralising SCF was
without effect. In contrast, neutralisation of IL-6 com-
pletely inhibited the survival effect indicating that survival
was mediated at least in part through IL-6. IL-6 is known
to prevent apoptosis in HLMC and cord blood-derived
mast cells (HCBMC) [25,26], and so this mechanism is
entirely plausible. It is further supported by the fact that
IL-6 mRNA expression was increased markedly in the
presence of IgE and this was paralleled by a small but sig-
nificant increase in the secretion of IL-6 protein into the
HLMC culture supernatant. The concentration of IL-6 in
the culture supernatant in the presence of 3 μg/ml IgE was
approximately 426 pg/ml. This is not far below the opti-
mal concentration of 1 ng/ml required to prevent apopto-
sis of HCBMC following growth factor withdrawal [25].
However, HLMC tend to aggregate in cell culture, and so
are likely to be exposed to much higher local concentra-
tions of HLMC-derived IL-6 than that present in the whole
culture supernatant. However, there was also approxi-
mately 355 pg/ml of IL-6 in the control supernatant in
which the HLMC had died, suggesting that although IL-6
promotes survival with IgE, a co-operative interaction
with IgE-dependent signalling is also likely. Indeed, a
study published while this paper was out for review dem-
onstrated that monomeric IgE alone induced the upregu-
lation of both mRNA and protein expression of the anti-
apoptotic Bcl-xL protein, whilst down-regulating the
expression of the pro-apoptotic proteins Puma and Bim
[27].
A study of the effects of anti-IgE therapy (omalizumab) on
airway inflammation in asthma identified a downward
Total IgE-induced IL-6 release into the supernatants at day 7  following cytokine withdrawal Figure 6
Total IgE-induced IL-6 release into the supernatants 
at day 7 following cytokine withdrawal. Data is pre-
sented as the mean ± SEM IL-6 release from six individual 
donors.
SYBR Green melting curve for quantitative real time RT-PCR Figure 4
SYBR Green melting curve for quantitative real time 
RT-PCR. The melting curves for human lung mast cell QRT-
PCR consistently gave a single peak with no evidence of non-
specific amplification or primer-dimerisation. The graph is 
from a single experiment and representative of all donors.
PCR products from the quantitative PCR experiments run on  an agarose gel Figure 5
PCR products from the quantitative PCR experi-
ments run on an agarose gel. PCR products from six 
donors were run on a 1.5% agarose gel to determine the size 
of the products. The product sizes corresponded to the 
expected size for both IL-6 and β-actin.BMC Immunology 2008, 9:2 http://www.biomedcentral.com/1471-2172/9/2
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trend in both epithelial and lamina propria mast cell
numbers of approximately 20% compared to control
although this did not reach statistical significance [28].
However this study was underpowered with only 14
patients in the omalizumab group and 14 patients in the
placebo group. There is therefore insufficient clinical data
at present to confirm or refute the in vivo relevance of our
in vitro findings regarding the ability of IgE to enhance
mast cell survival. An important feature of mast cell acti-
vation in the presence of IgE alone is that while free IgE is
present, intracellular signalling is sustained, whereas this
ceases as soon as free IgE is removed [14]. The mecha-
nisms behind this are still not known but indicate that
this signalling mechanism is likely to be important in vivo
where IgE exposure is continuous. Bearing in mind the
strong correlation between serum IgE and the presence of
asthma [29-32], it is conceivable that IgE contributes to
the increased numbers of mast cells evident in the airway
epithelium, mucosal glands and airway smooth muscle of
asthmatic subjects [5].
We have demonstrated recently that IgE in the absence of
antigen directly activates cultured HLMC leading to the
release of histamine, and the production of LTC4 and
CXCL8 [8]. The release of histamine and LTC4 was much
greater in the presence of SCF, a vital growth and differen-
tiation factor for human mast cells which also potentiates
IgE-dependent mediator release [22,33]. However in the
present study, when HLMC were incubated with IgE in the
absence of any exogenous cytokines substantial IL-6 pro-
duction was evident. This indicates that while SCF is
required for substantial histamine release [8], monomeric
IgE-induced cytokine production can proceed in it's
absence. This is in keeping with 2 studies of human cord
blood-derived mast cells (HCBMC) which failed to detect
histamine release in the absence of SCF but did demon-
strate the release of the chemokines CCL1, CCL2 and
CXCL8 [15,34]. The study of HCBMC by Matsuda and col-
leagues also failed to find any survival effect with IgE [15].
One factor which might explain the difference in response
between HLMC and HCBMC in terms of both histamine
release and survival is the degree of surface FcεRI expres-
sion. FcεRI expression is relatively low on HCBMC [35],
and demonstrates one example of the heterogeneity evi-
dent between mast cells from different tissues. Thus, mast
cells with higher FcεRI expression appear to be more reac-
tive to IgE, which may also contribute to the pro-survival
effect evident in this study. A second factor of relevance
may be the preparations of IgE used in the different stud-
ies. In mice, it has been demonstrated that some prepara-
tions of IgE are much more effective at promoting both
degranulation and cytokine-dependent survival
[10,16,36]. Although IL-6 is among those cytokines
released by mBMMC, recent studies suggest that IL-3, a
known growth factor for mouse BMMC, is the major
cytokine involved in their protection from cell death [21].
Matsuda and colleagues found that the sodium azide
present in their myeloma IgE preparation enhanced sur-
vival in the absence of IgE. For this reason, we ensured
that all of our experimental conditions contained an
equal amount of sodium azide, and included an appropri-
ate sodium azide control. We also found there to be a
small survival enhancing effect with the addition of
sodium azide to the cells, but this was far less marked than
that reported by Matsuda et al [15]. However the concen-
tration of azide in their experiments was 2 fold higher
than ours, although they showed there to be only around
6% difference in apoptotic cells between 0.0003%
sodium azide and concentrations 100 fold less [15].
Therefore, small differences in sodium azide concentra-
tion are very unlikely to have any great effect on the sur-
vival data.
Mast cell signalling and responses to IgE alone raise the
question as to whether the IgE preparations used are truly
monomeric or just complexes of IgE which mimic recep-
tor cross-linking with antigen, and whether the physiolog-
ical concentrations of IgE used in vitro induce IgE to self
aggregate at the receptor [37,38]. In fact, there is evidence
that like receptor crosslinking with allergen, the signalling
from IgE alone in the absence of allergen is also a result of
receptor aggregation [10]. However, there are several lines
of evidence which indicate that although receptor aggre-
gation is initiated, distinct signalling pathways are
recruited and that the effects of IgE alone are not an arte-
fact. For example, although influx of extracellular Ca2+ is a
critical requirement for mediator release in mast cells acti-
vated by either IgE alone or by antigen, the channels car-
rying Ca2+  into the cell following monomeric IgE
stimulation appear to be different [13]. In addition,
cytokine release induced by IgE alone is often much
greater than that initiated in antigen-stimulated cells
[11,17]. Furthermore, IgE induced Ca2+ influx requires
PKCβII whilst antigen-induced Ca2+ influx does not [11].
Interestingly, HPLC purification of human myeloma
monomeric IgE, which ensures that there are no multi/
dimeric complexes, does not abrogate the biological
response and, if anything, enhances it [15]. Furthermore,
while IgE induces marked IL-6 production from mouse
BMMC, IgE aggregates have no effect [17], confirming that
mast cell responses to IgE are not due to IgE aggregates.
There is therefore robust evidence that the greater the per-
centage of IgE monomers, the greater  the biological
response. All of these observations point towards distinct
signalling pathways in mast cells activated by IgE alone
versus antigen-dependent FcεRI cross-linking.BMC Immunology 2008, 9:2 http://www.biomedcentral.com/1471-2172/9/2
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Conclusion
In summary, we demonstrate that IgE in the absence of
antigen promotes HLMC survival in a dose-dependent
manner, and that this survival is markedly attenuated with
the addition of neutralising anti-IL-6 antibody. Since IL-6
mRNA transcription is dramatically upregulated with the
addition of IgE, and there is an increased release of IL-6
into the supernatant of IgE stimulated cells, we can con-
clude that the prosurvival effect of IgE in HLMC is due, at
least in part, to the autocrine production of IL-6. This
study provides a further mechanism through which IL-6
and IgE contribute to the pathogenesis of asthma, and
through which anti-IgE therapy might achieve its thera-
peutic effect.
Methods
Purification and culture of human lung mast cells
All human subjects gave written informed consent and the
study was approved by the Leicestershire Research Ethics
Committee, UK. Lung tissue was obtained by surgical
resection for bronchial carcinoma and mast cells isolated
as described previously [39]. The final HLMC purity was
>98% with cell viability >97% (monitored by exclusion of
trypan blue).
Following isolation, HLMC were cultured in DMEM/
Glutamax/HEPES containing 10% FBS, 1% MEM nones-
sential amino acids (all from Life Technologies), 1% anti-
biotic/antimycotic solution (Sigma-Aldrich), 100 ng/mL
recombinant human (rh)SCF, 50 ng/mL rhIL-6 and 10
ng/mL rhIL-10 (R&D, Abingdon, UK) at 37°C in a humid-
ified incubator flushed with 5% CO2 for a minimum of 4
weeks prior to experiments. Half of the medium was
changed every 7 days. HLMC purity remained unchanged
during the culture period.
HLMC survival assay
Long term cultured HLMC were counted using an haemo-
cytometer and cell viability assessed using exclusion of
trypan blue stain. HLMC were washed to remove the
cytokines present in the culture medium. 1 × 104 HLMC
were plated into each well of a 96 well cell culture plate in
50 μl of DMEM/10% FBS. 50 μl of 2× the final concentra-
tion of human myeloma IgE (Calbiochem-Novabiochem,
Nottingham, UK) or medium alone was added. IgE was
centrifuged at 14000 g for 20 min to remove any large
aggregates [8,15]. IgE preparations (100 μg/ml) contain
0.005% sodium azide. Therefore, dilutions of IgE were
prepared to give a final concentration of sodium azide of
0.00015% in all conditions (including a control) except
for the cytokine control (containing 100 ng/ml SCF, 50
ng/ml IL-6 and 10 ng/ml IL-10) and the no-azide control.
At the indicated time points from 1–10 days, wells were
aspirated and any adherent HLMC were removed using
trypsin solution (Fisher Scientific, Loughborough, UK).
Aspirated cells were transferred to a 96 well V bottom
plate and centrifuged at 300 × g for 5 minutes. Superna-
tants were removed and stored at -20°C and cells were
resuspended in 10 μl of DMEM. 10 μl of trypan blue solu-
tion was added to the cells and cell number and viability
were assessed using a haemocytometer.
For the determination of pro-survival cytokine activity in
the cultures, neutralising anti-human IL-6 (1 μg/ml)
(mouse IgG1), anti-human SCF (1 μg/ml) (goat polyclo-
nal IgG) or an isotype control (1 μg/ml) (mouse IgG1)
antibodies (all from R&D, Abingdon, UK) were added to
cultures containing 3 μg/ml IgE.
Isolation of HLMC total RNA
2 × 106 HLMC were incubated for 24 hours in growth
medium with or without 3 μg/ml IgE in 6 well plates.
Cells were aspirated and centrifuged at 250 × g for 8 min-
utes. Supernatants were removed and the cells resus-
pended in 25 ml of sterile PBS before centrifuging again.
Total RNA was then isolated using an SV Total RNA Isola-
tion System (Promega, Southampton, UK) according to
the manufacturer's instructions.
Quantitative real-time RT-PCR
Quantitative real time RT-PCR was performed using a sin-
gle tube Full Velocity SYBR Green Kit (Stratagene, Amster-
dam, Netherlands). Primers were designed for IL-6 to
span exon-exon junctions to eliminate DNA contamina-
tion issues. PCR products were designed to be between
200 and 300 base pairs in length in line with the optimum
length for SYBR green use. The Full Velocity SYBR Green
QRT-PCR kit uses a combined annealing/extension step of
60°C. Therefore, all primers were designed to have a Tm
within 1°C of 60°C. Primer3 software was used for the
design of the primers [40]. Primer sequences for IL-6 were:
forward primer 5'-GCACTGGCAGAAAACAACCT-3';
reverse primer 5'-CAGGGGTGGTTATTGCATCT-3'. The
product length for IL-6 was 253 bp.
The QRT-PCR reaction was optimised for each gene and
200 nM final concentration of primers was assessed as the
optimum for use over all conditions. Using this concen-
tration of primers ensured no non-specific amplification
occurred in the sample wells. Reverse transcription was
carried out for 30 minutes at 50°C before 5 minutes at
95°C was used to inactivate the reverse transcriptase
which otherwise interferes with the DNA polymerase. 50
cycles of 95°C for 20 seconds followed by 60°C for 30
seconds were carried out and fluorescence was collected at
the end of each extension cycle using the Mx3000P QPCR
machine (Stratagene). A SYBR green dissociation curve
was carried out at the end of the reactions to ensure spe-
cificity and products were run on 1.5% agarose gels to
determine product length. Products were gel purifiedBMC Immunology 2008, 9:2 http://www.biomedcentral.com/1471-2172/9/2
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(QIAGEN, Crawley, UK) and sequenced using the Protein
and Nucleic Acid Chemistry Laboratory, University of
Leicester.
For the comparative QRT-PCR, the internal normaliser
gene used was β-actin and all mRNA expression data were
normalised to β-actin and corrected using the reference
dye (ROX). The β-actin primer sequences used were: for-
ward primer – 5'-TTCAACTCCATCATGAAGTGTGACGTG
– 3', reverse primer – 5'-CTAAGTCATAGTCCGCCTA-
GAAGCATT – 3'. The product length for β-actin was 310
bp. Only experiments where a distinct single peak was
observed with a melting temperature different to that of
the no template control were used. Expression data was
expressed as the relative gene expression compared to the
calibrator (unstimulated cells) as determined by the
Mx3000P software's built in algorithm using an adaptive
baseline to determine the Ct.
Measurement of IL-6 in HLMC supernatants
Supernatants removed from the survival assays were
stored at -20°C prior to measurement of IL-6. Samples
were measured for IL-6 from conditions following 7 days
of cytokine withdrawal. IL-6 was measured using the
Quantikine human IL-6 ELISA kit (R&D, Abingdon, UK)
according to the manufacturer's instructions.
Statistical analysis
Data is presented as the mean ± SEM unless otherwise
stated. IL-6 release is presented as ng/106 cells. Differences
between paired data were evaluated using Student's paired
two-tailed t tests. Comparative quantitative RT-PCR data
is presented as the relative expression compared to control
(untreated cells) after correction against the internal cali-
brator β-actin as determined by the Mx3000P software's
built in algorithm using an adaptive baseline to determine
the Ct. Due to the inherent variability of relative expres-
sion data according to the algorithm used, relative expres-
sion was also calculated using the 2-ΔΔCt method [23] and
the Relative Expression Software Tool (REST 2005, version
1.9.12, Corbett Life Science). In the untreated cells, a Ct
value was not always achieved so the final cycle (cycle 50)
was assigned as the Ct which tends to underestimate the
degree of upregulation. Traditional statistical analyses for
quantitative PCR are not appropriate due to high variabil-
ity of gene expression in ex vivo human cells. Thus com-
parative QRT-PCR statistics were obtained by a hypothesis
test with randomised bootstrapping of values with 50,000
iterations using the Relative Expression Software Tool
(REST 2005, version 1.9.12, Corbett Life Science).
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